nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—Mental retardation—Capecitabine—esophageal cancer	0.0174	0.0484	CcSEcCtD
Tapentadol—Panic attack—Capecitabine—esophageal cancer	0.0102	0.0283	CcSEcCtD
Tapentadol—Drug hypersensitivity—Capecitabine—esophageal cancer	0.00943	0.0262	CcSEcCtD
Tapentadol—Altered state of consciousness—Capecitabine—esophageal cancer	0.00823	0.0229	CcSEcCtD
Tapentadol—Balance disorder—Capecitabine—esophageal cancer	0.00695	0.0193	CcSEcCtD
Tapentadol—Infection—Carboplatin—esophageal cancer	0.00623	0.0173	CcSEcCtD
Tapentadol—Dysarthria—Cisplatin—esophageal cancer	0.00545	0.0151	CcSEcCtD
Tapentadol—Memory impairment—Capecitabine—esophageal cancer	0.00484	0.0135	CcSEcCtD
Tapentadol—Dysarthria—Capecitabine—esophageal cancer	0.00402	0.0112	CcSEcCtD
Tapentadol—Lung disorder—Methotrexate—esophageal cancer	0.004	0.0111	CcSEcCtD
Tapentadol—Coordination abnormal—Capecitabine—esophageal cancer	0.00387	0.0108	CcSEcCtD
Tapentadol—Depressed level of consciousness—Capecitabine—esophageal cancer	0.00367	0.0102	CcSEcCtD
Tapentadol—Irritability—Cisplatin—esophageal cancer	0.00357	0.00992	CcSEcCtD
Tapentadol—Breast disorder—Cisplatin—esophageal cancer	0.00338	0.0094	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00337	0.00936	CcSEcCtD
Tapentadol—Nasopharyngitis—Cisplatin—esophageal cancer	0.00335	0.0093	CcSEcCtD
Tapentadol—Mental disability—Capecitabine—esophageal cancer	0.0033	0.00916	CcSEcCtD
Tapentadol—Abdominal discomfort—Cisplatin—esophageal cancer	0.0031	0.00862	CcSEcCtD
Tapentadol—Dysarthria—Methotrexate—esophageal cancer	0.00299	0.00831	CcSEcCtD
Tapentadol—Hot flush—Capecitabine—esophageal cancer	0.00295	0.00819	CcSEcCtD
Tapentadol—Menopausal symptoms—Capecitabine—esophageal cancer	0.00292	0.00812	CcSEcCtD
Tapentadol—Lethargy—Capecitabine—esophageal cancer	0.00281	0.00782	CcSEcCtD
Tapentadol—Osteoarthritis—Capecitabine—esophageal cancer	0.00276	0.00766	CcSEcCtD
Tapentadol—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00273	0.00759	CcSEcCtD
Tapentadol—Bradycardia—Cisplatin—esophageal cancer	0.00263	0.00732	CcSEcCtD
Tapentadol—Irritability—Capecitabine—esophageal cancer	0.00263	0.00732	CcSEcCtD
Tapentadol—Ataxia—Capecitabine—esophageal cancer	0.00259	0.00721	CcSEcCtD
Tapentadol—Urinary tract disorder—Cisplatin—esophageal cancer	0.00256	0.0071	CcSEcCtD
Tapentadol—Connective tissue disorder—Cisplatin—esophageal cancer	0.00254	0.00707	CcSEcCtD
Tapentadol—Urethral disorder—Cisplatin—esophageal cancer	0.00254	0.00705	CcSEcCtD
Tapentadol—Visual impairment—Cisplatin—esophageal cancer	0.00249	0.00693	CcSEcCtD
Tapentadol—Breast disorder—Capecitabine—esophageal cancer	0.00249	0.00693	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00248	0.0069	CcSEcCtD
Tapentadol—Nasopharyngitis—Capecitabine—esophageal cancer	0.00247	0.00685	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00243	0.00676	CcSEcCtD
Tapentadol—Eye disorder—Cisplatin—esophageal cancer	0.00242	0.00672	CcSEcCtD
Tapentadol—Cardiac disorder—Cisplatin—esophageal cancer	0.0024	0.00668	CcSEcCtD
Tapentadol—Immune system disorder—Cisplatin—esophageal cancer	0.00234	0.0065	CcSEcCtD
Tapentadol—Mediastinal disorder—Cisplatin—esophageal cancer	0.00233	0.00648	CcSEcCtD
Tapentadol—Abdominal discomfort—Capecitabine—esophageal cancer	0.00229	0.00635	CcSEcCtD
Tapentadol—HTR3A—vagus nerve—esophageal cancer	0.00227	0.502	CbGeAlD
Tapentadol—Malnutrition—Cisplatin—esophageal cancer	0.00225	0.00626	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00222	0.00616	CcSEcCtD
Tapentadol—Visual disturbance—Methotrexate—esophageal cancer	0.00217	0.00602	CcSEcCtD
Tapentadol—Weight decreased—Capecitabine—esophageal cancer	0.00216	0.00599	CcSEcCtD
Tapentadol—Infestation—Capecitabine—esophageal cancer	0.00213	0.00591	CcSEcCtD
Tapentadol—Infestation NOS—Capecitabine—esophageal cancer	0.00213	0.00591	CcSEcCtD
Tapentadol—Vision blurred—Cisplatin—esophageal cancer	0.00212	0.0059	CcSEcCtD
Tapentadol—Depression—Capecitabine—esophageal cancer	0.00212	0.00589	CcSEcCtD
Tapentadol—Tremor—Cisplatin—esophageal cancer	0.00211	0.00587	CcSEcCtD
Tapentadol—Lethargy—Methotrexate—esophageal cancer	0.0021	0.00582	CcSEcCtD
Tapentadol—Urinary tract infection—Capecitabine—esophageal cancer	0.00207	0.00574	CcSEcCtD
Tapentadol—Osteoarthritis—Methotrexate—esophageal cancer	0.00205	0.00571	CcSEcCtD
Tapentadol—Irritability—Methotrexate—esophageal cancer	0.00196	0.00545	CcSEcCtD
Tapentadol—Convulsion—Cisplatin—esophageal cancer	0.00195	0.00543	CcSEcCtD
Tapentadol—Bradycardia—Capecitabine—esophageal cancer	0.00194	0.0054	CcSEcCtD
Tapentadol—Ataxia—Methotrexate—esophageal cancer	0.00193	0.00537	CcSEcCtD
Tapentadol—Anxiety—Cisplatin—esophageal cancer	0.00191	0.00531	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.0019	0.00529	CcSEcCtD
Tapentadol—Hypoaesthesia—Capecitabine—esophageal cancer	0.0019	0.00528	CcSEcCtD
Tapentadol—Urinary tract disorder—Capecitabine—esophageal cancer	0.00188	0.00524	CcSEcCtD
Tapentadol—Connective tissue disorder—Capecitabine—esophageal cancer	0.00187	0.00521	CcSEcCtD
Tapentadol—Urethral disorder—Capecitabine—esophageal cancer	0.00187	0.0052	CcSEcCtD
Tapentadol—Breast disorder—Methotrexate—esophageal cancer	0.00186	0.00516	CcSEcCtD
Tapentadol—Oedema—Cisplatin—esophageal cancer	0.00184	0.00511	CcSEcCtD
Tapentadol—Anaphylactic shock—Cisplatin—esophageal cancer	0.00184	0.00511	CcSEcCtD
Tapentadol—Visual impairment—Capecitabine—esophageal cancer	0.00184	0.00511	CcSEcCtD
Tapentadol—Infection—Cisplatin—esophageal cancer	0.00183	0.00508	CcSEcCtD
Tapentadol—Nervous system disorder—Cisplatin—esophageal cancer	0.0018	0.00501	CcSEcCtD
Tapentadol—Tachycardia—Cisplatin—esophageal cancer	0.00179	0.00499	CcSEcCtD
Tapentadol—Skin disorder—Cisplatin—esophageal cancer	0.00179	0.00496	CcSEcCtD
Tapentadol—Eye disorder—Capecitabine—esophageal cancer	0.00178	0.00496	CcSEcCtD
Tapentadol—Hyperhidrosis—Cisplatin—esophageal cancer	0.00178	0.00494	CcSEcCtD
Tapentadol—Cardiac disorder—Capecitabine—esophageal cancer	0.00177	0.00492	CcSEcCtD
Tapentadol—Angiopathy—Capecitabine—esophageal cancer	0.00173	0.00481	CcSEcCtD
Tapentadol—Immune system disorder—Capecitabine—esophageal cancer	0.00172	0.00479	CcSEcCtD
Tapentadol—Mediastinal disorder—Capecitabine—esophageal cancer	0.00172	0.00478	CcSEcCtD
Tapentadol—Hypotension—Cisplatin—esophageal cancer	0.00172	0.00478	CcSEcCtD
Tapentadol—Chills—Capecitabine—esophageal cancer	0.00171	0.00476	CcSEcCtD
Tapentadol—Abdominal discomfort—Methotrexate—esophageal cancer	0.0017	0.00473	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00168	0.00466	CcSEcCtD
Tapentadol—Mental disorder—Capecitabine—esophageal cancer	0.00167	0.00465	CcSEcCtD
Tapentadol—Malnutrition—Capecitabine—esophageal cancer	0.00166	0.00462	CcSEcCtD
Tapentadol—Paraesthesia—Cisplatin—esophageal cancer	0.00165	0.00459	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00165	0.00458	CcSEcCtD
Tapentadol—Dyspnoea—Cisplatin—esophageal cancer	0.00164	0.00456	CcSEcCtD
Tapentadol—Erectile dysfunction—Methotrexate—esophageal cancer	0.00163	0.00454	CcSEcCtD
Tapentadol—Decreased appetite—Cisplatin—esophageal cancer	0.0016	0.00444	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00159	0.00441	CcSEcCtD
Tapentadol—Infestation—Methotrexate—esophageal cancer	0.00158	0.0044	CcSEcCtD
Tapentadol—Infestation NOS—Methotrexate—esophageal cancer	0.00158	0.0044	CcSEcCtD
Tapentadol—Depression—Methotrexate—esophageal cancer	0.00158	0.00438	CcSEcCtD
Tapentadol—Vision blurred—Capecitabine—esophageal cancer	0.00157	0.00435	CcSEcCtD
Tapentadol—Tremor—Capecitabine—esophageal cancer	0.00156	0.00432	CcSEcCtD
Tapentadol—Feeling abnormal—Cisplatin—esophageal cancer	0.00152	0.00421	CcSEcCtD
Tapentadol—Vertigo—Capecitabine—esophageal cancer	0.00149	0.00415	CcSEcCtD
Tapentadol—Syncope—Capecitabine—esophageal cancer	0.00149	0.00414	CcSEcCtD
Tapentadol—Palpitations—Capecitabine—esophageal cancer	0.00147	0.00408	CcSEcCtD
Tapentadol—Loss of consciousness—Capecitabine—esophageal cancer	0.00146	0.00406	CcSEcCtD
Tapentadol—Cough—Capecitabine—esophageal cancer	0.00145	0.00403	CcSEcCtD
Tapentadol—Arthralgia—Capecitabine—esophageal cancer	0.00141	0.00393	CcSEcCtD
Tapentadol—Anxiety—Capecitabine—esophageal cancer	0.00141	0.00392	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.0014	0.0039	CcSEcCtD
Tapentadol—Urinary tract disorder—Methotrexate—esophageal cancer	0.0014	0.0039	CcSEcCtD
Tapentadol—Urethral disorder—Methotrexate—esophageal cancer	0.00139	0.00387	CcSEcCtD
Tapentadol—Dry mouth—Capecitabine—esophageal cancer	0.00138	0.00384	CcSEcCtD
Tapentadol—Visual impairment—Methotrexate—esophageal cancer	0.00137	0.0038	CcSEcCtD
Tapentadol—Confusional state—Capecitabine—esophageal cancer	0.00137	0.0038	CcSEcCtD
Tapentadol—Oedema—Capecitabine—esophageal cancer	0.00136	0.00377	CcSEcCtD
Tapentadol—Hypersensitivity—Cisplatin—esophageal cancer	0.00135	0.00377	CcSEcCtD
Tapentadol—Infection—Capecitabine—esophageal cancer	0.00135	0.00374	CcSEcCtD
Tapentadol—Shock—Capecitabine—esophageal cancer	0.00133	0.00371	CcSEcCtD
Tapentadol—Nervous system disorder—Capecitabine—esophageal cancer	0.00133	0.00369	CcSEcCtD
Tapentadol—Eye disorder—Methotrexate—esophageal cancer	0.00133	0.00369	CcSEcCtD
Tapentadol—Tachycardia—Capecitabine—esophageal cancer	0.00132	0.00368	CcSEcCtD
Tapentadol—Asthenia—Cisplatin—esophageal cancer	0.00132	0.00367	CcSEcCtD
Tapentadol—Cardiac disorder—Methotrexate—esophageal cancer	0.00132	0.00366	CcSEcCtD
Tapentadol—Skin disorder—Capecitabine—esophageal cancer	0.00132	0.00366	CcSEcCtD
Tapentadol—Hyperhidrosis—Capecitabine—esophageal cancer	0.00131	0.00364	CcSEcCtD
Tapentadol—Angiopathy—Methotrexate—esophageal cancer	0.00129	0.00358	CcSEcCtD
Tapentadol—Immune system disorder—Methotrexate—esophageal cancer	0.00128	0.00357	CcSEcCtD
Tapentadol—Mediastinal disorder—Methotrexate—esophageal cancer	0.00128	0.00356	CcSEcCtD
Tapentadol—Chills—Methotrexate—esophageal cancer	0.00127	0.00354	CcSEcCtD
Tapentadol—Hypotension—Capecitabine—esophageal cancer	0.00127	0.00352	CcSEcCtD
Tapentadol—Diarrhoea—Cisplatin—esophageal cancer	0.00126	0.0035	CcSEcCtD
Tapentadol—Mental disorder—Methotrexate—esophageal cancer	0.00124	0.00346	CcSEcCtD
Tapentadol—Malnutrition—Methotrexate—esophageal cancer	0.00124	0.00344	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00123	0.00343	CcSEcCtD
Tapentadol—Insomnia—Capecitabine—esophageal cancer	0.00123	0.00341	CcSEcCtD
Tapentadol—Paraesthesia—Capecitabine—esophageal cancer	0.00122	0.00338	CcSEcCtD
Tapentadol—Dyspnoea—Capecitabine—esophageal cancer	0.00121	0.00336	CcSEcCtD
Tapentadol—Dyspepsia—Capecitabine—esophageal cancer	0.00119	0.00332	CcSEcCtD
Tapentadol—Decreased appetite—Capecitabine—esophageal cancer	0.00118	0.00327	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00117	0.00325	CcSEcCtD
Tapentadol—Vomiting—Cisplatin—esophageal cancer	0.00117	0.00325	CcSEcCtD
Tapentadol—Fatigue—Capecitabine—esophageal cancer	0.00117	0.00325	CcSEcCtD
Tapentadol—Vision blurred—Methotrexate—esophageal cancer	0.00117	0.00324	CcSEcCtD
Tapentadol—Rash—Cisplatin—esophageal cancer	0.00116	0.00322	CcSEcCtD
Tapentadol—Constipation—Capecitabine—esophageal cancer	0.00116	0.00322	CcSEcCtD
Tapentadol—Dermatitis—Cisplatin—esophageal cancer	0.00116	0.00322	CcSEcCtD
Tapentadol—Feeling abnormal—Capecitabine—esophageal cancer	0.00112	0.0031	CcSEcCtD
Tapentadol—Vertigo—Methotrexate—esophageal cancer	0.00111	0.00309	CcSEcCtD
Tapentadol—Nausea—Cisplatin—esophageal cancer	0.00109	0.00304	CcSEcCtD
Tapentadol—Cough—Methotrexate—esophageal cancer	0.00108	0.003	CcSEcCtD
Tapentadol—Urticaria—Capecitabine—esophageal cancer	0.00108	0.00299	CcSEcCtD
Tapentadol—Convulsion—Methotrexate—esophageal cancer	0.00107	0.00298	CcSEcCtD
Tapentadol—Arthralgia—Methotrexate—esophageal cancer	0.00105	0.00293	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00105	0.00291	CcSEcCtD
Tapentadol—Confusional state—Methotrexate—esophageal cancer	0.00102	0.00283	CcSEcCtD
Tapentadol—Anaphylactic shock—Methotrexate—esophageal cancer	0.00101	0.0028	CcSEcCtD
Tapentadol—Infection—Methotrexate—esophageal cancer	0.001	0.00279	CcSEcCtD
Tapentadol—Hypersensitivity—Capecitabine—esophageal cancer	0.000999	0.00278	CcSEcCtD
Tapentadol—Nervous system disorder—Methotrexate—esophageal cancer	0.00099	0.00275	CcSEcCtD
Tapentadol—Skin disorder—Methotrexate—esophageal cancer	0.00098	0.00272	CcSEcCtD
Tapentadol—Hyperhidrosis—Methotrexate—esophageal cancer	0.000975	0.00271	CcSEcCtD
Tapentadol—Asthenia—Capecitabine—esophageal cancer	0.000972	0.0027	CcSEcCtD
Tapentadol—Pruritus—Capecitabine—esophageal cancer	0.000959	0.00267	CcSEcCtD
Tapentadol—Hypotension—Methotrexate—esophageal cancer	0.000943	0.00262	CcSEcCtD
Tapentadol—Diarrhoea—Capecitabine—esophageal cancer	0.000927	0.00258	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000919	0.00256	CcSEcCtD
Tapentadol—Insomnia—Methotrexate—esophageal cancer	0.000913	0.00254	CcSEcCtD
Tapentadol—Paraesthesia—Methotrexate—esophageal cancer	0.000906	0.00252	CcSEcCtD
Tapentadol—Dyspnoea—Methotrexate—esophageal cancer	0.0009	0.0025	CcSEcCtD
Tapentadol—Somnolence—Methotrexate—esophageal cancer	0.000897	0.00249	CcSEcCtD
Tapentadol—Dizziness—Capecitabine—esophageal cancer	0.000896	0.00249	CcSEcCtD
Tapentadol—Dyspepsia—Methotrexate—esophageal cancer	0.000888	0.00247	CcSEcCtD
Tapentadol—Decreased appetite—Methotrexate—esophageal cancer	0.000877	0.00244	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000871	0.00242	CcSEcCtD
Tapentadol—Fatigue—Methotrexate—esophageal cancer	0.00087	0.00242	CcSEcCtD
Tapentadol—Vomiting—Capecitabine—esophageal cancer	0.000862	0.0024	CcSEcCtD
Tapentadol—Rash—Capecitabine—esophageal cancer	0.000855	0.00238	CcSEcCtD
Tapentadol—Dermatitis—Capecitabine—esophageal cancer	0.000854	0.00237	CcSEcCtD
Tapentadol—Headache—Capecitabine—esophageal cancer	0.000849	0.00236	CcSEcCtD
Tapentadol—Feeling abnormal—Methotrexate—esophageal cancer	0.000831	0.00231	CcSEcCtD
Tapentadol—Nausea—Capecitabine—esophageal cancer	0.000805	0.00224	CcSEcCtD
Tapentadol—Urticaria—Methotrexate—esophageal cancer	0.000802	0.00223	CcSEcCtD
Tapentadol—Hypersensitivity—Methotrexate—esophageal cancer	0.000743	0.00207	CcSEcCtD
Tapentadol—Asthenia—Methotrexate—esophageal cancer	0.000724	0.00201	CcSEcCtD
Tapentadol—Pruritus—Methotrexate—esophageal cancer	0.000714	0.00198	CcSEcCtD
Tapentadol—Diarrhoea—Methotrexate—esophageal cancer	0.00069	0.00192	CcSEcCtD
Tapentadol—Dizziness—Methotrexate—esophageal cancer	0.000667	0.00185	CcSEcCtD
Tapentadol—Vomiting—Methotrexate—esophageal cancer	0.000642	0.00178	CcSEcCtD
Tapentadol—Rash—Methotrexate—esophageal cancer	0.000636	0.00177	CcSEcCtD
Tapentadol—Dermatitis—Methotrexate—esophageal cancer	0.000636	0.00177	CcSEcCtD
Tapentadol—Headache—Methotrexate—esophageal cancer	0.000632	0.00176	CcSEcCtD
Tapentadol—Nausea—Methotrexate—esophageal cancer	0.000599	0.00167	CcSEcCtD
Tapentadol—UGT1A9—digestive system—esophageal cancer	0.000438	0.0969	CbGeAlD
Tapentadol—UGT2B7—digestive system—esophageal cancer	0.000353	0.0781	CbGeAlD
Tapentadol—HTR3A—digestive system—esophageal cancer	0.000257	0.057	CbGeAlD
Tapentadol—UGT2B7—Metabolism—GSTT1—esophageal cancer	0.00023	0.000362	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CYP2A6—esophageal cancer	0.000228	0.000358	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—GHRL—esophageal cancer	0.000226	0.000355	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PFN1—esophageal cancer	0.000225	0.000353	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GAPDH—esophageal cancer	0.000223	0.00035	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CRABP1—esophageal cancer	0.000221	0.000347	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—XIAP—esophageal cancer	0.000217	0.000341	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ENO1—esophageal cancer	0.000216	0.000339	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTGS1—esophageal cancer	0.000216	0.000339	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000215	0.000339	CbGpPWpGaD
Tapentadol—HTR3A—lung—esophageal cancer	0.000215	0.0476	CbGeAlD
Tapentadol—OPRK1—Signaling Pathways—PDE4D—esophageal cancer	0.000213	0.000336	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PSME2—esophageal cancer	0.000213	0.000334	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PSME1—esophageal cancer	0.000213	0.000334	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000212	0.000334	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GNG7—esophageal cancer	0.00021	0.00033	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—BLVRB—esophageal cancer	0.000207	0.000325	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC52A3—esophageal cancer	0.000207	0.000325	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CTNNA1—esophageal cancer	0.000205	0.000323	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CXCL2—esophageal cancer	0.000204	0.000321	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—GNG7—esophageal cancer	0.000203	0.000319	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ELMO1—esophageal cancer	0.000202	0.000317	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AKAP13—esophageal cancer	0.000197	0.00031	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ALDH2—esophageal cancer	0.000197	0.000309	CbGpPWpGaD
Tapentadol—SLC6A4—digestive system—esophageal cancer	0.000196	0.0435	CbGeAlD
Tapentadol—OPRD1—Signaling Pathways—PSME2—esophageal cancer	0.000191	0.0003	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PSME1—esophageal cancer	0.000191	0.0003	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.00019	0.000299	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.00019	0.000299	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—XIAP—esophageal cancer	0.00019	0.000299	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ANXA1—esophageal cancer	0.00019	0.000298	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC52A3—esophageal cancer	0.000189	0.000297	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—BLVRB—esophageal cancer	0.000189	0.000297	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—GSTT1—esophageal cancer	0.000187	0.000294	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000185	0.000291	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CYP2A6—esophageal cancer	0.000185	0.000291	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SST—esophageal cancer	0.000184	0.00029	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000184	0.00029	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CYP1B1—esophageal cancer	0.000183	0.000288	CbGpPWpGaD
Tapentadol—SLC6A2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000182	0.000287	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000182	0.000286	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PDE4D—esophageal cancer	0.00018	0.000284	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CTNNA1—esophageal cancer	0.00018	0.000283	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—GHRL—esophageal cancer	0.00018	0.000283	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NOTCH3—esophageal cancer	0.00018	0.000283	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CXCL2—esophageal cancer	0.000179	0.000281	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—FBXW7—esophageal cancer	0.000177	0.000278	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC10A2—esophageal cancer	0.000176	0.000277	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CA1—esophageal cancer	0.000176	0.000277	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTGS1—esophageal cancer	0.000175	0.000276	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ENO1—esophageal cancer	0.000175	0.000276	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PSME2—esophageal cancer	0.000173	0.000272	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PSME1—esophageal cancer	0.000173	0.000272	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CYP19A1—esophageal cancer	0.000172	0.000271	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—GNG7—esophageal cancer	0.000172	0.00027	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000169	0.000265	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PSME1—esophageal cancer	0.000167	0.000263	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PSME2—esophageal cancer	0.000167	0.000263	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ANXA1—esophageal cancer	0.000166	0.000262	CbGpPWpGaD
Tapentadol—SLC6A4—lung—esophageal cancer	0.000164	0.0363	CbGeAlD
Tapentadol—CYP2C19—digestive system—esophageal cancer	0.000163	0.036	CbGeAlD
Tapentadol—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000162	0.000255	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CA1—esophageal cancer	0.000162	0.000255	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SST—esophageal cancer	0.000162	0.000254	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NOTCH2—esophageal cancer	0.000161	0.000254	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CA2—esophageal cancer	0.000161	0.000253	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—XIAP—esophageal cancer	0.000161	0.000253	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC10A2—esophageal cancer	0.00016	0.000252	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CA1—esophageal cancer	0.00016	0.000252	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—GHRL—esophageal cancer	0.000158	0.000248	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NOTCH3—esophageal cancer	0.000158	0.000248	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—HMOX1—esophageal cancer	0.000157	0.000248	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000157	0.000247	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—FBXW7—esophageal cancer	0.000155	0.000244	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CTNNA1—esophageal cancer	0.000152	0.000239	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CXCL2—esophageal cancer	0.000151	0.000238	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ABCB1—esophageal cancer	0.000151	0.000238	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	0.000151	0.000237	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PLCE1—esophageal cancer	0.00015	0.000235	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ADH7—esophageal cancer	0.00015	0.000235	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CYP1B1—esophageal cancer	0.000149	0.000234	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CA2—esophageal cancer	0.000148	0.000233	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000148	0.000233	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CA2—esophageal cancer	0.000147	0.000231	CbGpPWpGaD
Tapentadol—SLC6A2—lung—esophageal cancer	0.000144	0.032	CbGeAlD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000143	0.000226	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TGFBR2—esophageal cancer	0.000143	0.000225	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NOTCH2—esophageal cancer	0.000141	0.000222	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PSME2—esophageal cancer	0.000141	0.000222	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PSME1—esophageal cancer	0.000141	0.000222	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ANXA1—esophageal cancer	0.000141	0.000221	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CYP19A1—esophageal cancer	0.00014	0.00022	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000138	0.000216	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000138	0.000216	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SST—esophageal cancer	0.000137	0.000215	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PLCE1—esophageal cancer	0.000136	0.000215	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ADH7—esophageal cancer	0.000136	0.000215	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SMAD4—esophageal cancer	0.000135	0.000213	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000135	0.000212	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NOTCH3—esophageal cancer	0.000133	0.00021	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—GHRL—esophageal cancer	0.000133	0.00021	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ADH1B—esophageal cancer	0.000131	0.000206	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—FBXW7—esophageal cancer	0.000131	0.000206	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—HMOX1—esophageal cancer	0.000128	0.000201	CbGpPWpGaD
Tapentadol—CYP2C9—digestive system—esophageal cancer	0.000126	0.0279	CbGeAlD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	0.000125	0.000197	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TGFBR2—esophageal cancer	0.000125	0.000197	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TYMP—esophageal cancer	0.000125	0.000197	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ABCB1—esophageal cancer	0.000123	0.000193	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP26A1—esophageal cancer	0.000122	0.000192	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000121	0.00019	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ADH1B—esophageal cancer	0.00012	0.000188	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NOTCH2—esophageal cancer	0.000119	0.000188	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALOX15—esophageal cancer	0.000119	0.000187	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SMAD4—esophageal cancer	0.000119	0.000187	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000115	0.000181	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TYMP—esophageal cancer	0.000114	0.00018	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTO1—esophageal cancer	0.000113	0.000178	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TPI1—esophageal cancer	0.000113	0.000178	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.000112	0.000176	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP26A1—esophageal cancer	0.000111	0.000175	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HIF1A—esophageal cancer	0.000111	0.000174	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000109	0.000172	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALDOB—esophageal cancer	0.000109	0.000171	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALOX15—esophageal cancer	0.000108	0.00017	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TGFBR2—esophageal cancer	0.000106	0.000167	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KDR—esophageal cancer	0.000106	0.000167	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GAPDH—esophageal cancer	0.000105	0.000165	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTO1—esophageal cancer	0.000104	0.000164	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TPI1—esophageal cancer	0.000104	0.000164	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CRABP1—esophageal cancer	0.000104	0.000163	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTO1—esophageal cancer	0.000103	0.000163	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TPI1—esophageal cancer	0.000103	0.000163	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—CREBBP—esophageal cancer	0.000101	0.000159	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SMAD4—esophageal cancer	0.0001	0.000158	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALDOB—esophageal cancer	0.0001	0.000157	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NOTCH1—esophageal cancer	9.98e-05	0.000157	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALDOB—esophageal cancer	9.91e-05	0.000156	CbGpPWpGaD
Tapentadol—SLC6A2—lymph node—esophageal cancer	9.87e-05	0.0219	CbGeAlD
Tapentadol—CYP2C19—Metabolism—GNG7—esophageal cancer	9.86e-05	0.000155	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HIF1A—esophageal cancer	9.71e-05	0.000153	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GAPDH—esophageal cancer	9.62e-05	0.000151	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GAPDH—esophageal cancer	9.54e-05	0.00015	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CRABP1—esophageal cancer	9.54e-05	0.00015	CbGpPWpGaD
Tapentadol—CYP2D6—digestive system—esophageal cancer	9.46e-05	0.0209	CbGeAlD
Tapentadol—CYP2C9—Metabolism—CRABP1—esophageal cancer	9.45e-05	0.000149	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KDR—esophageal cancer	9.29e-05	0.000146	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	9.28e-05	0.000146	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALDH2—esophageal cancer	9.24e-05	0.000145	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GNG7—esophageal cancer	9.07e-05	0.000143	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CREBBP—esophageal cancer	9.05e-05	0.000142	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—NOS3—esophageal cancer	9.04e-05	0.000142	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GNG7—esophageal cancer	8.99e-05	0.000141	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—EGFR—esophageal cancer	8.89e-05	0.00014	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTT1—esophageal cancer	8.79e-05	0.000138	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NOTCH1—esophageal cancer	8.75e-05	0.000138	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP2A6—esophageal cancer	8.69e-05	0.000137	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	8.66e-05	0.000136	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALDH2—esophageal cancer	8.5e-05	0.000134	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—PIK3CA—esophageal cancer	8.5e-05	0.000134	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALDH2—esophageal cancer	8.43e-05	0.000133	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTGS2—esophageal cancer	8.27e-05	0.00013	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTGS1—esophageal cancer	8.24e-05	0.00013	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ENO1—esophageal cancer	8.24e-05	0.00013	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HIF1A—esophageal cancer	8.21e-05	0.000129	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CREBBP—esophageal cancer	8.2e-05	0.000129	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PSME1—esophageal cancer	8.12e-05	0.000128	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PSME2—esophageal cancer	8.12e-05	0.000128	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NOS3—esophageal cancer	8.1e-05	0.000127	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTT1—esophageal cancer	8.09e-05	0.000127	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTT1—esophageal cancer	8.02e-05	0.000126	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP2A6—esophageal cancer	7.99e-05	0.000126	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CREBBP—esophageal cancer	7.93e-05	0.000125	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP2A6—esophageal cancer	7.92e-05	0.000125	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	7.89e-05	0.000124	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KDR—esophageal cancer	7.85e-05	0.000124	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—EGFR—esophageal cancer	7.8e-05	0.000123	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—PIK3CA—esophageal cancer	7.72e-05	0.000121	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ERBB2—esophageal cancer	7.58e-05	0.000119	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTGS1—esophageal cancer	7.58e-05	0.000119	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ENO1—esophageal cancer	7.58e-05	0.000119	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTGS1—esophageal cancer	7.51e-05	0.000118	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ENO1—esophageal cancer	7.51e-05	0.000118	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PSME1—esophageal cancer	7.47e-05	0.000117	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PSME2—esophageal cancer	7.47e-05	0.000117	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—PIK3CA—esophageal cancer	7.45e-05	0.000117	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PSME1—esophageal cancer	7.4e-05	0.000116	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PSME2—esophageal cancer	7.4e-05	0.000116	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NOTCH1—esophageal cancer	7.4e-05	0.000116	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—NOS3—esophageal cancer	7.34e-05	0.000116	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NOS3—esophageal cancer	7.1e-05	0.000112	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	7.09e-05	0.000112	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP1B1—esophageal cancer	7e-05	0.00011	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—EP300—esophageal cancer	6.87e-05	0.000108	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PIK3CA—esophageal cancer	6.77e-05	0.000106	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTGS2—esophageal cancer	6.72e-05	0.000106	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CREBBP—esophageal cancer	6.71e-05	0.000105	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCND1—esophageal cancer	6.7e-05	0.000105	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ERBB2—esophageal cancer	6.65e-05	0.000105	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—EGFR—esophageal cancer	6.59e-05	0.000104	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP19A1—esophageal cancer	6.59e-05	0.000104	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CDKN1A—esophageal cancer	6.48e-05	0.000102	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	6.46e-05	0.000102	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP1B1—esophageal cancer	6.44e-05	0.000101	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP1B1—esophageal cancer	6.39e-05	0.0001	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PIK3CA—esophageal cancer	6.3e-05	9.91e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EP300—esophageal cancer	6.16e-05	9.7e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP19A1—esophageal cancer	6.06e-05	9.53e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—HMOX1—esophageal cancer	6.01e-05	9.45e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP19A1—esophageal cancer	6e-05	9.45e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NOS3—esophageal cancer	6e-05	9.45e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.9e-05	9.27e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCND1—esophageal cancer	5.87e-05	9.24e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ABCB1—esophageal cancer	5.77e-05	9.07e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PIK3CA—esophageal cancer	5.72e-05	9e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CDKN1A—esophageal cancer	5.68e-05	8.93e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ERBB2—esophageal cancer	5.62e-05	8.84e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—EP300—esophageal cancer	5.59e-05	8.79e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—HMOX1—esophageal cancer	5.53e-05	8.69e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—HMOX1—esophageal cancer	5.48e-05	8.62e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EP300—esophageal cancer	5.4e-05	8.5e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.38e-05	8.46e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MYC—esophageal cancer	5.37e-05	8.45e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ABCB1—esophageal cancer	5.3e-05	8.35e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ABCB1—esophageal cancer	5.26e-05	8.27e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EGFR—esophageal cancer	5.25e-05	8.26e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CA—esophageal cancer	5.09e-05	8e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCND1—esophageal cancer	4.96e-05	7.81e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CDKN1A—esophageal cancer	4.8e-05	7.55e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MYC—esophageal cancer	4.71e-05	7.41e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EGFR—esophageal cancer	4.61e-05	7.25e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EP300—esophageal cancer	4.57e-05	7.18e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CA—esophageal cancer	4.56e-05	7.17e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TP53—esophageal cancer	4.41e-05	6.94e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.36e-05	6.86e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CA—esophageal cancer	4.13e-05	6.5e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CA—esophageal cancer	4e-05	6.29e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MYC—esophageal cancer	3.98e-05	6.26e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.98e-05	6.26e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EGFR—esophageal cancer	3.89e-05	6.12e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TP53—esophageal cancer	3.87e-05	6.08e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CREBBP—esophageal cancer	3.85e-05	6.06e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CREBBP—esophageal cancer	3.55e-05	5.58e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CREBBP—esophageal cancer	3.51e-05	5.53e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NOS3—esophageal cancer	3.45e-05	5.43e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CA—esophageal cancer	3.38e-05	5.32e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TP53—esophageal cancer	3.27e-05	5.14e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NOS3—esophageal cancer	3.17e-05	4.99e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTGS2—esophageal cancer	3.16e-05	4.97e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NOS3—esophageal cancer	3.15e-05	4.95e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTGS2—esophageal cancer	2.9e-05	4.57e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTGS2—esophageal cancer	2.88e-05	4.53e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—EP300—esophageal cancer	2.63e-05	4.13e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—EP300—esophageal cancer	2.41e-05	3.8e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—EP300—esophageal cancer	2.39e-05	3.77e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CA—esophageal cancer	1.94e-05	3.06e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.79e-05	2.81e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.77e-05	2.79e-05	CbGpPWpGaD
